Drug intelligence / Profile preview

PS18

Development stage: Preclinical
Lead developer: Givaudan
Modality: Peptides
Administration: Intracerebroventricular

Overview

PS18 is a prosaposin-derived 18-mer peptide analog that exhibits neurotrophic and anti-apoptotic properties. It has been shown to reduce neuronal damage and apoptosis, particularly by antagonizing endoplasmic reticulum (ER) stress. In models of Parkinson's disease, PS18 significantly reduced dopaminergic neuronal loss and ER stress markers such as PERK, ATF6, CHOP, and BiP, suggesting a neuroprotective role. Its mechanism of action involves mitigating ER stress, which is implicated in neurodegenerative processes.

Other names: prosaposin-derived 18-mer peptideprosaposin-derived18-mer peptideprosaposin-derived-18-mer peptide

Targets

EIF2AK3 (Pkr-like endoplasmic reticulum kinase)ATF6 (Activating transcription factor 6 alpha)HSPA5 (Heat shock protein family A member 5)DDIT3 (DNA damage-inducible transcript 3 protein)

Beyond the preview

Go deeper on PS18.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PS18.

Explore the full profile